Company history

  • 3 Generations at the Head of the Family Business

    1929 - Foundation by Ramon Reig Jofre.

    1970 - Juan M. Biosca, son-in-law of the founder.

    2006 - Ignasi Biosca, grandson of the founder and current CEO.

  • Building-up of a Comprehensive Portfolio of Derma and Respiratory Prescription Products and OTC

    1964-1999 - Through the combination of own developments and several acquisitions in Spain.

     

  • Specialisation in Freeze-Dried Injectable Generics

    1978-2009
    Through the combination of own developments and several acquisitions of production capacity in Spain.

    • 1978 - Acquisition of first lyophilizer.
    • 1998 - Acquisition of Boehringer Ingelheim’s factory in Barcelona (ES) and setting up of central headquarters.
    • 2009 - New manufacturing plant of sterile freeze-dried vials in Barcelona (ES).

    Spearhead of internationalisation through out-licensing agreements and contract development and manufacturing for other companies.

  • Specialisation in Antibiotics

    1989-2004
    Through the combination of own developments and several acquisitions of production capacity in Spain.

    • 2000 - Acquisition of GlaxoSmithKline’s factory of penicillin antibiotics in Toledo (ES).
    • 2003 - New plant of injectable cephalosporin antibiotics in Toledo (ES).
    • 2004 - Acquisition antibiotic MAs Anaclosil, Pulmictan, Ardine and ArdineClav.

    Spearhead of internationalisation through out-licensing agreements and contract development and manufacturing for other companies.

  • Moving from Exports to Direct International Presence

    2009-today

    • 2009 - Acquisition of Bioglan (Sw) specializing in topical pharmaceutical formulations.
    • 2014 - Incorporation of RJ UK Ltd to centralize the commercial activity of Reig Jofre in UK.
    • 2014 - Incorporation of RJ Europe Pte Ltd, joint-venture in Singapore to market pharma products in ASEAN countries.
    • 2014 - Acquisition of international logistic center in Spain to Jansen (Johnson & Johnson Group).

  • Reinvesting Cashflows in R+D and Open Innovation Agreements

    2013-today

    • New indications, and new routes of administration and dosage of known active principles.
    • Development of beta-lactam antibiotic generics in all dosage forms, but with a special focus on freeze-dried injections.
    • New innovative molecules in partnership with start-ups and research centres.
    • Topical dermatological products, OTCs and nutritional supplements.

  • Reig Jofre Becomes #5 Spanish Pharma Co. by Turnover on the Spanish Stock Exchange

    December 2014 - Reig Jofre merges with public company Natraceutical, a reference in Europe in the field of food supplements sold in pharmacies through the brand Forté Pharma.

     

This site uses only technical third party cookies to provide better service, when browsing this website you agree to its use. See ourlegal advice. Agree

DMC Firewall is developed by Dean Marshall Consultancy Ltd